Tranexamic Acid: Low-Cost Drug Saves Lives in Trauma and Head Injury Cases
核心洞察
Tranexamic acid has become a standard of care for severe injury, significantly reducing mortality in trauma patients worldwide.
The CRASH-3 trial demonstrated that tranexamic acid reduces head injury deaths by 20%, marking it as a neuroprotective drug.
Ongoing research, including the CRASH-4 trial, explores tranexamic acid's potential in preventing death and disability in older adults with mild head injuries.
Tranexamic acid, a low-cost drug, has been proven to save thousands of lives in trauma and head injury cases, leading to significant changes in treatment practices worldwide. The initial breakthrough came from the CRASH-2 trial, which established tranexamic acid as the standard of care for severe injuries. This has led to its inclusion in the World Health Organization's list of essential medicines in 2010.
Impact on Trauma Care
In England, NICE guidelines in 2016 recommended administering tranexamic acid to trauma patients within 3 hours of injury. By the end of 2016, 90% of patients with severe injuries received tranexamic acid, a stark contrast to nearly 0% in 2010. The British and US Armies have also incorporated tranexamic acid into their combat care treatment guidelines. In 2019, the UK government invested £5 million to develop a tranexamic acid autoinjector for self-administration by injured soldiers awaiting medical assistance.
Expansion to Head Injury Treatment
Building on the success of CRASH-2, the NIHR-funded CRASH-3 trial investigated the impact of early tranexamic acid treatment on deaths from traumatic head injury (搜索), which affects approximately 40,000 people in the UK and 69 million worldwide annually. The CRASH-3 trial, involving 12,000 head injury patients across 175 hospitals globally, demonstrated that tranexamic acid reduces head injury deaths by 20%. According to Professor Roberts, this marked "an important breakthrough and the first neuroprotective drug for patients with head injury."
Intramuscular Injection and Paramedic Use
Recent findings have supported the effectiveness of intramuscular injections of tranexamic acid. The Manchester Arena Bombing Inquiry report in 2022 further emphasized the importance of tranexamic acid, recommending that paramedics administer it via intramuscular injection to save time during mass casualty events. The NHS ambulance service updated its policy in 2023 to align with these recommendations, and Professor Roberts is part of an NHS group promoting the use of intramuscular tranexamic acid by UK paramedics.
Ongoing Research: CRASH-4 Trial
The ongoing CRASH-4 trial, supported by £3 million in NIHR funding, is currently evaluating the role of tranexamic acid in preventing death and disability among older adults with mild head injuries. This research aims to further expand the applications of tranexamic acid and improve outcomes for a broader range of patients.